Gene info: ID 238

Gene: ALK

GENE ID: 238

Synonyms: CD246|NBLST3

Description: ALK receptor tyrosine kinase

Gene type: protein-coding

Location: 2p23.2-p23.1

dbXrefs: Ensembl:ENSG00000171094 MIM:105590 Vega:OTTHUMG00000152034 UniprotKB:Q9UM73

RefSeq: NG_009445.1

Retrived from: PubMed|SNP Mapped

SNPs: 7 ANCO-SNPs

Phenotype: CD|ND|AD

# Publications: 229

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 1.386e-2 (AD) 1.356e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs4520995	chr2:29895520 (GRCh38.p7)	T>C	alcohol dependence	SNV(Single Nucleotide Variation)
rs12473275	chr2:29562915 (GRCh38.p7)	G>A	alcohol dependence	SNV(Single Nucleotide Variation)
rs10193521	chr2:29562813 (GRCh38.p7)	G>A	alcohol dependence	SNV(Single Nucleotide Variation)
rs7592571	chr2:29545028 (GRCh38.p7)	C>A / C>T	alcohol dependence	SNV(Single Nucleotide Variation)
rs12467802	chr2:29524308 (GRCh38.p7)	C>G / C>T	alcohol dependence	SNV(Single Nucleotide Variation)
rs7580476	chr2:29460692 (GRCh38.p7)	C>T	alcohol dependence	SNV(Single Nucleotide Variation)
rs12617579	chr2:29266754 (GRCh38.p7)	C>T	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg12252328	chr2:29512828	ALK	Gene body	1.825e-4	Alcohol use disorders	26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
LGI2	0.734
AFAP1	0.722
KIAA1211	0.694
AMOTL1	0.693
DAB1	0.664
SH3RF3	0.64
PCDHGC4	0.634
MAFB	0.628
NPR3	0.626
VTI1A	0.625

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
ACOT6	-0.296
OR4F5	-0.296
KIF19	-0.295
RHBDL2	-0.288
ABHD1	-0.283
SLC14A1	-0.279
TPPP2	-0.274
IZUMO4	-0.272
APOA1	-0.27
NRN1L	-0.27

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00171	ATP	Small Molecule	56-65-5	Investigational\|Nutraceutical	Target
DB08865	Crizotinib	Small Molecule	877399-52-5	Approved	Target
DB09063	Ceritinib	Small Molecule	1032900-25-6	Approved	Target
DB11363	Alectinib	Small Molecule	-	Approved\|Investigational	Target
DB12267	Brigatinib	Small Molecule	1197953-54-0	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C448659	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin results in decreased stability of ALK protein mutant form	22912387
C054919	2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene	"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"	19422813
C026805	2,4-diaminopyridine	"2,4-diaminopyridine analog binds to and results in decreased activity of ALK protein"	22564207
C017205	2,4-diaminopyrimidine	"2,4-diaminopyrimidine analog results in decreased phosphorylation of ALK protein mutant form"	20979473
C017205	2,4-diaminopyrimidine	"ALK gene SNP inhibits the reaction [2,4-diaminopyrimidine analog results in decreased phosphorylation of ALK protein mutant form]"	20979473\|2097947
C017205	2,4-diaminopyrimidine	"ALK gene SNP results in decreased susceptibility to 2,4-diaminopyrimidine analog"	20979473
C023035	3,4,5,3',4'-pentachlorobiphenyl	"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of ALK mRNA"	28973690
C558529	9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one	"ALK protein mutant form results in decreased susceptibility to 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one"	22789543
C562235	9-ethyl-6,6-dimethyl-8-(4-oxetan-3-ylpiperazin-1-yl)-11-oxo-6,11-dihydro-5H-benzo(b)carbazole-3-carbonitrile	"9-ethyl-6,6-dimethyl-8-(4-oxetan-3-ylpiperazin-1-yl)-11-oxo-6,11-dihydro-5H-benzo(b)carbazole-3-carbonitrile results in decreased activity of ALK protein"	21823617
D000111	Acetylcysteine	Acetylcysteine affects the phosphorylation of and affects the activity of ALK protein mutant form	19503098
D000255	Adenosine Triphosphate	ALK protein binds to Adenosine Triphosphate	22072639
D000255	Adenosine Triphosphate	ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]	22072639
D000255	Adenosine Triphosphate	[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib	22072639
D000452	Aldrin	"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"	19422813
D000452	Aldrin	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
D000535	Aluminum	[APP protein modified form binds to Aluminum] which results in decreased expression of ALK mRNA	21298039
D000638	Amiodarone	Amiodarone results in increased expression of ALK mRNA	19774075
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of ALK mRNA	16483693
D001151	Arsenic	Arsenic affects the methylation of ALK gene	25304211
D001280	Atrazine	Atrazine results in decreased expression of ALK mRNA	22378314
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ALK mRNA	22300585
C006780	bisphenol A	bisphenol A results in decreased expression of ALK mRNA	25181051
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of ALK mRNA	20350560
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ALK gene	20938992
C551994	crizotinib	crizotinib results in decreased activity of ALK protein mutant form	21838707
C551994	crizotinib	ALK gene mutant form results in decreased susceptibility to crizotinib	22277784
C551994	crizotinib	ALK gene SNP inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein mutant form]	20979473\|2097947
C551994	crizotinib	ALK gene SNP results in decreased susceptibility to crizotinib	20979473
C551994	crizotinib	ALK protein mutant form inhibits the reaction [crizotinib binds to and results in decreased activity of ALK protein]	22659414
C551994	crizotinib	ALK protein mutant form inhibits the reaction [crizotinib results in decreased activity of ALK protein]	21030459
C551994	crizotinib	ALK protein mutant form inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]	21948233
C551994	crizotinib	[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib	22072639
C551994	crizotinib	ALK protein mutant form results in decreased susceptibility to crizotinib	21791641\|2194823
C551994	crizotinib	crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]	23104988
C551994	crizotinib	crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]	23104988
C551994	crizotinib	crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]	22286764
C551994	crizotinib	crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]	22286764
C551994	crizotinib	crizotinib results in decreased activity of ALK protein	21030459\|2181241
C551994	crizotinib	crizotinib results in decreased activity of ALK protein mutant form	21767331\|2183870
C551994	crizotinib	crizotinib results in decreased phosphorylation of ALK protein	21502504\|2194823
C551994	crizotinib	crizotinib results in decreased phosphorylation of ALK protein mutant form	20979473
C551994	crizotinib	crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form	23104988
C551994	crizotinib	crizotinib results in decreased stability of ALK protein mutant form	22912387
C551994	crizotinib	crizotinib results in increased mutagenesis of ALK gene mutant form	20979473\|2150250
C551994	crizotinib	[crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to crizotinib	20979473\|2150250
C551994	crizotinib	crizotinib results in increased mutagenesis of ALK protein mutant form	21030459
C551994	crizotinib	[crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to crizotinib	21030459
C551994	crizotinib	[crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein	21030459
C551994	crizotinib	[Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]	22034911
C551994	crizotinib	[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib	22034911
C551994	crizotinib	crizotinib results in decreased activity of ALK protein mutant form	21838707
C551994	crizotinib	crizotinib binds to ALK protein	21812414
C551994	crizotinib	crizotinib results in decreased activity of ALK protein	21823617
D003634	DDT	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
D013759	Dronabinol	ALK mutant form promotes the reaction [Dronabinol results in decreased phosphorylation of NUPR1 protein]	21233844
D013759	Dronabinol	ALK mutant form promotes the reaction [Dronabinol results in increased expression of NUPR1 mRNA]	21233844
D013759	Dronabinol	ALK mutant form promotes the reaction [Dronabinol results in increased expression of TRIB3 mRNA]	21233844
D013759	Dronabinol	ALK results in decreased susceptibility to Dronabinol	21233844
D013759	Dronabinol	[NVP-TAE684 results in decreased phosphorylation of ALK protein] which results in increased susceptibility to Dronabinol	21233844
D003632	Dichlorodiphenyldichloroethane	"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"	19422813
D003632	Dichlorodiphenyldichloroethane	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
D003633	Dichlorodiphenyl Dichloroethylene	"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"	19422813
D003633	Dichlorodiphenyl Dichloroethylene	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of ALK mRNA	26924002
D004026	Dieldrin	"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA"	19422813
D004026	Dieldrin	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
C024629	dimethyl phthalate	dimethyl phthalate affects the expression of ALK mRNA	26924002
D004732	Endrin	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of ALK protein	21948233\|2203491
D005038	Ethylnitrosourea	[Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]	22034911
D005038	Ethylnitrosourea	[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib	22034911
D005038	Ethylnitrosourea	[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to NVP-TAE684	22034911
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ALK gene	20938992
D004397	Fonofos	Fonofos results in increased methylation of ALK promoter	22847954
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased phosphorylation of ALK protein mutant form	19503098
D001556	Lindane	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
D009637	Masoprocol	Masoprocol affects the phosphorylation of and affects the activity of ALK protein mutant form	19503098
D009637	Masoprocol	Masoprocol results in decreased activity of ALK protein	19503098
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ALK gene	20938992
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of ALK mRNA	26924002
C562237	N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide	"ALK protein modified form results in increased susceptibility to N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide"	21859094
C562237	N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide	"[ALK protein modified form results in increased susceptibility to N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide] which results in increased activity of CASP3 protein"	21859094
C562237	N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide	"[ALK protein modified form results in increased susceptibility to N-(2-(2-(4-(4-(2-hydroxypropyl)piperazin-1-yl)-2-methoxyphenylamino)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)phenyl)-N-methylmethanesulfonamide] which results in increased activity of CASP7 protein"	21859094
C568507	N-(2-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)ethyl)glycyrrhetinamide	"N-(2-(3-(3,5-bis(trifluoromethyl)phenyl)ureido)ethyl)glycyrrhetinamide results in decreased activity of ALK protein"	21888390
C056614	N-(3-phenoxycinnamyl)acetohydroxamic acid	N-(3-phenoxycinnamyl)acetohydroxamic acid results in decreased activity of ALK protein	19503098
C516714	NVP-TAE684	NVP-TAE684 results in decreased activity of ALK protein mutant form	21838707
C516714	NVP-TAE684	ALK protein mutant form inhibits the reaction [NVP-TAE684 results in decreased phosphorylation of ALK protein]	21948233
C516714	NVP-TAE684	ALK protein mutant form results in decreased susceptibility to NVP-TAE684	21791641\|2194823
C516714	NVP-TAE684	EGF protein inhibits the reaction [NVP-TAE684 results in decreased phosphorylation of ALK protein]	22843788
C516714	NVP-TAE684	[Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to NVP-TAE684	22034911
C516714	NVP-TAE684	HGF protein inhibits the reaction [NVP-TAE684 results in decreased phosphorylation of ALK protein]	22553343
C516714	NVP-TAE684	NVP-TAE684 inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]	22286764
C516714	NVP-TAE684	NVP-TAE684 inhibits the reaction [ALK protein results in increased expression of MYCN protein]	22286764
C516714	NVP-TAE684	NVP-TAE684 results in decreased activity of ALK protein mutant form	21030459\|2183870
C516714	NVP-TAE684	NVP-TAE684 results in decreased phosphorylation of ALK protein	21233844\|2150250
C516714	NVP-TAE684	[NVP-TAE684 results in decreased phosphorylation of ALK protein] which results in increased susceptibility to Dronabinol	21233844
C516714	NVP-TAE684	NVP-TAE684 results in decreased activity of ALK protein mutant form	21838707
C009618	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of ALK mRNA"	21673326
D010278	Parathion	Parathion results in increased methylation of ALK promoter	22847954
D000068437	Pemetrexed	ALK gene mutant form affects the susceptibility to Pemetrexed	21336183
C551178	PF-04254644	PF-04254644 affects the activity of ALK protein	20231546
D011441	Propylthiouracil	Propylthiouracil results in increased expression of ALK mRNA	24780913
D019821	Simvastatin	[Lindane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA	28263720
C017947	sodium arsenite	sodium arsenite affects the expression of ALK mRNA	19590694
C112765	tanespimycin	tanespimycin results in decreased activity of ALK protein mutant form	21030459
C112765	tanespimycin	tanespimycin results in decreased expression of ALK protein	21502504
C112765	tanespimycin	tanespimycin results in decreased expression of ALK protein modified form	21502504
C012568	terbufos	terbufos results in increased methylation of ALK promoter	22847954
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ALK mRNA	21570461\|2637764
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of ALK mRNA	19465110
D014212	Tretinoin	[Tretinoin co-treated with ALK gene mutant form] results in increased cleavage of CASP3 protein	20576349
D014212	Tretinoin	Tretinoin results in decreased expression of ALK mRNA	20576349
D014212	Tretinoin	Tretinoin results in decreased expression of ALK protein	20576349
D014212	Tretinoin	Tretinoin results in increased expression of ALK mRNA	23724009
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of ALK mRNA	19042947
D014638	Vanadates	Vanadates analog results in increased phosphorylation of ALK protein mutant form	19503098
D014639	Vanadium	Vanadium results in decreased expression of ALK mRNA	19000753
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of ALK gene	25560391

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004704	NF-kappaB-inducing kinase activity	-	TAS	19459784
GO:0004709	MAP kinase kinase kinase activity	-	IBA	21873635
GO:0004713	protein tyrosine kinase activity	-	IBA	21873635
GO:0004713	protein tyrosine kinase activity	-	IDA	9174053
GO:0004714	transmembrane receptor protein tyrosine kinase activity	-	IBA	21873635
GO:0004714	transmembrane receptor protein tyrosine kinase activity	-	IDA	9174053
GO:0004714	transmembrane receptor protein tyrosine kinase activity	-	TAS	19459784
GO:0004888	transmembrane signaling receptor activity	-	IBA	21873635
GO:0005515	protein binding	-	IPI	15680399 17681947 22939624 26418745
GO:0005524	ATP binding	-	IEA	-
GO:0031434	mitogen-activated protein kinase kinase binding	-	IBA	21873635
GO:0042802	identical protein binding	-	IPI	25517749

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000187	activation of MAPK activity	-	TAS	19459784
GO:0001934	positive regulation of protein phosphorylation	-	IBA	21873635
GO:0007165	signal transduction	-	TAS	19459784
GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	-	IEA	-
GO:0007275	multicellular organism development	-	IBA	21873635
GO:0008283	cell proliferation	-	TAS	19459784
GO:0009968	negative regulation of signal transduction	-	IBA	21873635
GO:0016310	phosphorylation	-	IDA	9174053
GO:0016310	phosphorylation	-	TAS	19459784
GO:0018108	peptidyl-tyrosine phosphorylation	-	IEA	-
GO:0021766	hippocampus development	-	IEA	-
GO:0030154	cell differentiation	-	IBA	21873635
GO:0030534	adult behavior	-	IEA	-
GO:0033674	positive regulation of kinase activity	-	IBA	21873635
GO:0036269	swimming behavior	-	IEA	-
GO:0038061	NIK/NF-kappaB signaling	-	IEA	-
GO:0042127	regulation of cell proliferation	-	IEA	-
GO:0042981	regulation of apoptotic process	-	TAS	19459784
GO:0043066	negative regulation of apoptotic process	-	IBA	21873635
GO:0046777	protein autophosphorylation	-	IDA	9174053
GO:0046777	protein autophosphorylation	-	TAS	19459784
GO:0048666	neuron development	-	TAS	19459784
GO:0051092	positive regulation of NF-kappaB transcription factor activity	-	TAS	19459784
GO:0060159	regulation of dopamine receptor signaling pathway	-	IEA	-
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	IBA	21873635
GO:0090648	response to environmental enrichment	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005622	intracellular	-	IEA	-
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005886	plasma membrane	-	IDA	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635
GO:0005887	integral component of plasma membrane	-	IDA	9174053
GO:0005887	integral component of plasma membrane	-	TAS	19459784
GO:0032991	protein-containing complex	-	IDA	23382219
GO:0043235	receptor complex	-	IBA	21873635
GO:0070062	extracellular exosome	-	HDA	19056867

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
28065467	Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases. (2017 Jul)	Rokutan-Kurata M	Clin Lung Cancer
26677401	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. (2015)	Garajova I	Clin Epigenetics
26898615	K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. (2016 Mar)	Mengoli MC	Lung Cancer
21703634	A meta-analysis of two genome-wide association studies identifies 3 new loci for alcohol dependence. (2011 Nov)	Wang KS	J Psychiatr Res
27064578	Epidemiology of Lung Cancer in Korea: Recent Trends. (2016 Apr)	Park JY	Tuberc Respir Dis (Seoul)
25966792	Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. (2015 Jun)	Cui S	Med Oncol
29199691	New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. (2017 Jan-Mar)	Dubey AP	Indian J Cancer
27646887	[Expression of ALK protein in 7 371 pulmonary adenocarcinoma samples, with analysis of clinicopathologic features]. (2016 Sep 8)	Zhao RY	Zhonghua Bing Li Xue Za Zhi
25360721	Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. (2014)	Wang Y	PLoS One
28860576	PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. (2017 Aug 31)	Zhang M	Sci Rep
24466154	Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. (2014)	Ko JH	PLoS One
25126481	Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene. (2014 Aug 1)	Choong ML	Biores Open Access
28683775	ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. (2017 Jul 6)	Mamesaya N	BMC Cancer
22548013	Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. (2012 Jan)	Nguyen KS	J Oncol Pract
24959902	Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. (2014)	Fan L	PLoS One
28468034	[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung]. (2017 May 8)	Sun PL	Zhonghua Bing Li Xue Za Zhi
29610932	EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib. (2018 May)	Huang T	Cancer Chemother Pharmacol
24888607	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. (2014 Sep)	Kim TJ	J Surg Oncol
23661716	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (2013 Oct)	Ou SH	J Clin Pathol
24442099	Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. (2014 Mar)	Wang J	J Cancer Res Clin Oncol
28468033	[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. (2017 May 8)	Hou LK	Zhonghua Bing Li Xue Za Zhi
27217997	Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. (2016)	Sag SO	Springerplus
29151522	Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib. (2018 Mar 1)	Hayashi N	Intern Med
20659620	Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. (2010 Sep)	Murakami S	Lung Cancer
29191580	Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. (2017 Oct)	Wang Z	Lung Cancer
25773866	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. (2015 May)	Tsai TH	Lung Cancer
29167001	[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. (2017 Nov 20)	Chen M	Zhongguo Fei Ai Za Zhi
25349974	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. (2015 Jan 6)	D'Incecco A	Br J Cancer
23788756	The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. (2013 Sep)	Kim HR	Ann Oncol
25695224	Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. (2015 Mar)	Gleeson FC	J Thorac Oncol
28806935	Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. (2017 Aug 15)	Zhao L	BMC Pulm Med
27438512	Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. (2018 Apr)	Jia X	Appl Immunohistochem Mol Morphol
26923333	Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. (2016 Feb 29)	Shi X	Sci Rep
28373815	Systemic treatment of non-small cell lung cancer brain metastases. (2016)	Cedrych I	Contemp Oncol (Pozn)
28514931	Lung cancer in never-smokers - what are the differences? (2017 Jul)	Dias M	Acta Oncol
26893860	Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb)	Furukawa M	Mol Clin Oncol
19671850	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. (2009 Aug 15)	Rodig SJ	Clin Cancer Res
22605530	Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. (2012 Dec 1)	Paik PK	Cancer
25745045	No impact of passive smoke on the somatic profile of lung cancers in never-smokers. (2015 May)	Couraud S	Eur Respir J
25567908	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)	Drilon A	Clin Cancer Res
21178715	Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. (2011 Jan)	Laack E	J Thorac Oncol
21420271	[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. (2011 Apr)	Hadoux J	Presse Med
23551194	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jun)	Lindeman NI	Arch Pathol Lab Med
26601054	Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. (2015)	Rangachari D	Cancer Treat Commun
25833149	Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. (2015)	de Melo AC	Oncology
29631966	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. (2018 Mar 17)	Reis H	Clin Lung Cancer
24850843	FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. (2014 Aug 1)	Wang R	Clin Cancer Res
27298405	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. (2016 Aug 20)	Rusthoven CG	J Clin Oncol
24477503	Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. (2014 Jun)	Lee YG	Thromb Haemost
29661733	Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina. (2018 Feb 26)	Verzura M	Ann Diagn Pathol
21655907	Lung cancers unrelated to smoking: characterized by single oncogene addiction? (2011 Aug)	Suda K	Int J Clin Oncol
23802852	Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)	McQuitty E	Arch Pathol Lab Med
25243942	Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. (2015 Jan)	Jeong CJ	Clin Nucl Med
24942490	ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. (2014 Nov)	Tuononen K	Genes Chromosomes Cancer
26202550	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. (2015 Dec)	Zheng D	Ann Surg Oncol
27467545	Adipophilin expression in lung adenocarcinoma is associated with apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases. (2017 Jan)	Fujimoto M	Histopathology
28210129	Targeted inhibition in tumors with ALK dependency. (2013)	Kwak EL	Lung Cancer (Auckl)
25361983	Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. (2015 Jan)	Kobayashi Y	Ann Oncol
23738762	Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. (2014 May)	Hwang DH	Arch Pathol Lab Med
23877438	CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. (2013 Oct)	Matsuura S	Oncol Rep
29228652	Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung. (2017 Nov 17)	Yu R	Oncotarget
27001591	Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. (2016 May 1)	Presley CJ	J Clin Oncol
27943404	The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. (2017 May)	Skov BG	Histopathology
24388371	Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. (2014 Jan)	Kobayashi M	Respir Investig
24362875	Fishing for ALK with immunohistochemistry may predict response to crizotinib. (2013 Sep-Oct)	Bavieri M	Tumori
27500967	ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. (2016 Oct)	Bal A	APMIS
25180059	Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. (2014 Jun)	Zhao C	Transl Oncol
29744229	ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib. (2018)	Sagawa R	Case Rep Oncol Med
27561692	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. (2016 Aug 25)	Peretti U	Respir Res
23988776	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. (2014 Mar)	Warth A	Eur Respir J
26705279	[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation]. (2015 Sep)	Zhong S	Zhonghua Bing Li Xue Za Zhi
25267753	How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. (2014 Nov 10)	Zwicker JI	J Clin Oncol
29656747	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. (2018 May)	Fujimoto D	Lung Cancer
28285691	Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. (2017 Apr)	Halpenny DF	Lung Cancer
23515407	Characteristics of lung cancers harboring NRAS mutations. (2013 May 1)	Ohashi K	Clin Cancer Res
25657019	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. (2015 May)	Couraud S	Eur Respir J
26955281	The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. (2016)	Zheng D	Onco Targets Ther
25557162	Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells. (2015 Mar)	Pareja F	Cancer Cytopathol
29449735	ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma". (2017 Dec)	Mengoli MC	Pathologica
22483782	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. (2012 Aug)	Fukui T	Lung Cancer
25870798	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. (2015 Apr)	Kohno T	Transl Lung Cancer Res
26164066	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep)	Preusser M	Eur J Cancer
25582278	EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. (2015 Mar)	Yang Y	Lung Cancer
28685219	Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma. (2018 Jul)	Pyo JS	Pathol Oncol Res
28676214	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. (2017 Aug)	Takamochi K	Lung Cancer
20614325	Solitary fibrous tumor of the larynx. (2008 Jun)	Thompson LD	Head Neck Pathol
25152623	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. (2014)	Hu H	Onco Targets Ther
24589437	Prospective screening for ALK: clinical features and outcome according to ALK status. (2014 May)	Fallet V	Eur J Cancer
29128428	Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. (2018 Jan)	Ferrara R	J Thorac Oncol
16819319	Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. (2006 Jul)	Harik LR	Am J Surg Pathol
28050149	Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study. (2016 Dec)	Kayaniyil S	Curr Oncol
25288236	Molecular alterations in non-small cell lung carcinomas of the young. (2014 Dec)	VandenBussche CJ	Hum Pathol
23552377	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jul)	Lindeman NI	J Thorac Oncol
23932486	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. (2013 Oct)	Yamaguchi N	Lung Cancer
29682332	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? (2018)	Pinto JA	ESMO Open
24723496	Cytomorphology of non-small cell lung carcinoma with anaplastic lymphoma kinase gene rearrangement. (2015 Jan)	Toll AD	Diagn Cytopathol
24346098	Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation. (2014 Jan)	Tufman AL	J Thorac Oncol
27766545	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? (2016 Dec)	D'Argento E	Curr Treat Options Oncol
23928533	[Detection of EML4-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation]. (2013 Apr)	Zhong S	Zhonghua Bing Li Xue Za Zhi
28433570	Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. (2017 Sep)	Soo RA	Clin Lung Cancer
26350052	Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review. (2016 Feb)	Rafael OC	Int J Surg Pathol
27987580	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. (2016 Dec)	Chapman AM	Lung Cancer
26392858	ALK-rearranged squamous cell carcinoma of the lung. (2015 Sep)	Takanashi Y	Respirol Case Rep
24729716	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014)	Li H	Onco Targets Ther
28559820	Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer. (2017 Jan-Apr)	Yamasaki M	Case Rep Oncol
25914136	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. (2015 Jun)	Guerin A	Cancer Epidemiol
22768234	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)	An SJ	PLoS One
23919423	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. (2013 Oct)	Xia N	Exp Lung Res
27008586	Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. (2017 Jan)	Bu S	Ann Surg Oncol
27281559	Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer. (2016 Dec 1)	Wang E	Clin Cancer Res
28644837	Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. (2017)	Abernethy AP	PLoS One
25789627	Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. (2015)	Hsu KH	PLoS One
21336183	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. (2011 Apr)	Camidge DR	J Thorac Oncol
27086595	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. (2016 May)	Lee T	J Pathol Transl Med
29683890	Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. (2018 Apr 20)	Tseng JS	J Immunother
27100677	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. (2016)	Sato K	PLoS One
27262212	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug)	Noonan SA	J Thorac Oncol
24920890	Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis. (2014)	Primiani A	Int J Chron Obstruct Pulmon Dis
25855381	Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. (2015 Jun 1)	Saito M	Cancer Res
22317764	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. (2012 Apr 1)	Zhang Y	Clin Cancer Res
21562939	Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. (2011 Aug)	Yano T	Int J Clin Oncol
26623133	Epithelioid inflammatory myofibroblastic sarcoma: a case report. (2015 Oct)	Sarmiento DE	J Thorac Dis
29277178	[Clinical Significance and Mechanism of PI3K p110beta Overexpression in Non-small Cell Lung Cancer]. (2017 Dec 20)	Xiong Y	Zhongguo Fei Ai Za Zhi
25862146	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. (2015 Jun)	Chang YL	Lung Cancer
25588859	Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. (2015 May 26)	Campos-Gomez S	Int J Biol Markers
26767032	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. (2014 Sep)	Zhu J	Thorac Cancer
23856136	[Prognosis related clinical and molecular factors in malignant pleural mesothelioma]. (2013 Mar)	Wang YY	Zhonghua Jie He He Hu Xi Za Zhi
28513466	Non-small cell lung cancer - mutations, targeted and combination therapy. (2017 May 17)	Kutkowska J	Postepy Hig Med Dosw (Online)
28423587	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. (2017 Apr 4)	Yang H	Oncotarget
27103824	Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. (2016)	Wen M	Onco Targets Ther
26253541	Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. (2015 Aug 8)	Fu S	Chin J Cancer
27330767	Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report. (2016 Jul)	Yamamoto Y	Mol Clin Oncol
26200269	Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)	Shim HS	J Thorac Oncol
22975805	The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)	Seo JS	Genome Res
25407901	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. (2014 Nov 18)	Guo Y	BMC Cancer
29413057	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. (2018 Feb)	VanderLaan PA	Lung Cancer
28534101	Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique. (2017 Dec)	Nicos M	Clin Transl Oncol
27142166	ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. (2016 May 3)	Incharoen P	World J Surg Oncol
26739511	Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. (2016 Jan 7)	Yang Y	Sci Rep
22707299	Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov)	Ren S	Cell Biochem Biophys
27646667	[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement]. (2017 May)	Caliez J	Rev Mal Respir
18166835	EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. (2008 Jan)	Inamura K	J Thorac Oncol
28104537	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma. (2017 May)	Rangachari D	J Thorac Oncol
23664446	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. (2013 Aug)	Ali G	Lung Cancer
23677552	[Gender-specific difference in lung cancer]. (2013 May)	Serke M	Pneumologie
24755712	Evidence that the lung Adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood. (2014 Jul)	Ryan BM	Cancer Epidemiol Biomarkers Prev
24828667	Small-cell lung cancers in patients who never smoked cigarettes. (2014 Jun)	Varghese AM	J Thorac Oncol
28494184	Current status of research and treatment for non-small cell lung cancer in never-smoking females. (2017 Jun 3)	Saito S	Cancer Biol Ther
21483012	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011 May 20)	Paik PK	J Clin Oncol
27188576	Non-small-cell lung cancer. (2015 May 21)	Gridelli C	Nat Rev Dis Primers
27635639	Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. (2017 Nov 2)	Song Z	Cancer Biol Ther
29123416	Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer. (2017)	Tufman A	Onco Targets Ther
2135058	Serum choline esterase and liver function among a group of organophosphorus pesticides sprayers in Egypt. (1990 Nov-Dec)	Kamal AA	J Toxicol Clin Exp
29413048	Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? (2018 Feb)	Zhou F	Lung Cancer
11931612	GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). (2002 Apr 11)	Benedetti P	J Med Chem
28103968	[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong]. (2017 Jan 20)	Qiao X	Zhongguo Fei Ai Za Zhi
22736493	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. (2012 Oct)	Shaozhang Z	Genes Chromosomes Cancer
7466143	[Early liver damage caused by alcohol]. (1980 Oct-Dec)	Garca Vigil JL	Rev Gastroenterol Mex
15499043	Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. (2005 Jan)	Kerner A	Arterioscler Thromb Vasc Biol
28210164	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. (2016)	Leprieur EG	Lung Cancer (Auckl)
18242762	EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. (2008 Aug)	Shinmura K	Lung Cancer
27033383	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)	Chen LF	Zhonghua Bing Li Xue Za Zhi
26536196	Clinical Implications of Variant ALK FISH Rearrangement Patterns. (2015 Nov)	Gao X	J Thorac Oncol
25113306	US lung cancer trends by histologic type. (2014 Sep 15)	Lewis DR	Cancer
25007143	Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec)	Boland JM	Am J Surg Pathol
23150706	RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. (2012 Dec 10)	Wang R	J Clin Oncol
23341890	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. (2013)	Li Y	PLoS One
27470969	PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? (2016 Sep 15)	Gettinger S	Clin Cancer Res
25434695	A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. (2014 Dec 1)	Hong S	Sci Rep
26752591	Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area. (2017 May)	Dutton JW 3rd	Addict Biol
27573756	Crizotinib resistance: implications for therapeutic strategies. (2016 Sep)	Dagogo-Jack I	Ann Oncol
20130484	Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. (2010 Apr)	Ou SH	J Thorac Oncol
23098378	Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan)	Li H	Lung Cancer
21062932	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. (2010 Nov 15)	Camidge DR	Clin Cancer Res
26582178	The performance of NLST screening criteria in Asian lung cancer patients. (2015 Nov 18)	Kumar V	BMC Cancer
26208325	Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015)	Chatziandreou I	PLoS One
27027665	Gene aberrations for precision medicine against lung adenocarcinoma. (2016 Jun)	Saito M	Cancer Sci
26788139	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. (2015 Dec)	Ren W	Oncol Lett
28280984	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. (2018 Jan)	Saito M	Surg Today
28118634	Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement. (2017)	Lin D	Oncol Res Treat
28024691	Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. (2017 Jan)	Demidova I	Lung Cancer
23251849	Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. (2012 Dec)	Suda K	Aging Dis
26273395	Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. (2015 Jul)	Wu S	Thorac Cancer
21933749	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011 Oct)	Shaw AT	Lancet Oncol
26775573	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. (2016 Jan)	Hamard C	Ann Pathol
27793199	Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China. (2016 Oct 28)	Li X	BMC Cancer
24279718	Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. (2013 Nov 26)	Rossing HH	BMC Res Notes
22887466	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. (2013 Jan)	Shaw AT	Ann Oncol
29530732	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. (2018 Feb 21)	Petrelli F	Clin Lung Cancer
28210171	Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer. (2016)	Legius B	Lung Cancer (Auckl)
27655296	Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. (2016 Sep 21)	Brcic L	Diagn Pathol
28507205	A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. (2017 Jul)	Wang VE	Oncologist
22464348	Lung cancer in never smokers--a review. (2012 Jun)	Couraud S	Eur J Cancer
25922742	Anaplastic lymphoma kinase-positive lung adenocarcinoma patient with development of sick sinus syndrome while on targeted treatment with crizotinib. (2015 Mar)	Jiang H	J Thorac Dis
27799390	Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases. (2016 Nov)	Ruano-Ravina A	Eur Respir J
25706305	Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. (2015)	Zhao F	PLoS One
25738220	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)	Sholl LM	J Thorac Oncol
23562183	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. (2013 Jul)	Lindeman NI	J Mol Diagn
23052178	EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis. (2012 Jul-Aug)	Lazarev I	Tumori
26437441	Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks. (2015 Sep 30)	Seki Y	Biomolecules
27747151	A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation. (2016)	Imamura F	Respir Med Case Rep
19234440	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (2009 Apr)	Inamura K	Mod Pathol
26762747	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. (2016 Jan)	Michels S	J Thorac Oncol
23723294	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)	Dearden S	Ann Oncol
26888425	Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients. (2016 May)	Tian G	Future Oncol
28840008	Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. (2017 Jul)	Zhang J	J Thorac Dis
28881815	Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. (2017 Aug 8)	Dugay F	Oncotarget
29799009	Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. (2018 May 24)	Wang C	Nat Commun
23887156	ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. (2013 Sep)	Sholl LM	Am J Surg Pathol
22980554	[Cavitating nodules in a 40-year-old non-smoking woman: a very particular tumour]. (2012 Sep)	Albahary MV	Rev Mal Respir
27446444	Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). (2016 Aug)	Sanchez-Ares M	Oncol Lett
29764592	[Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer]. (2018 May 20)	Zhang X	Zhongguo Fei Ai Za Zhi
26946429	Dependence-induced ethanol drinking and GABA neurotransmission are altered in Alk deficient mice. (2016 Aug)	Schweitzer P	Neuropharmacology
19667264	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009 Sep 10)	Shaw AT	J Clin Oncol
20926401	EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. (2010 Oct 15)	Sakairi Y	Clin Cancer Res
23439505	Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. (2013)	Furukawa M	Acta Med Okayama
25327654	[ALK protein expression and gene fusion in bronchoscopic specimens of lung adenocarcinoma]. (2014 Jul)	Liang X	Zhonghua Zhong Liu Za Zhi
29137260	Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. (2017 Oct 10)	Dong Y	Oncotarget
28914263	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. (2018 Feb)	Tang Z	Mod Pathol
29191596	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. (2017 Oct)	Brody R	Lung Cancer
24643262	Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (2014 Apr)	Ou SH	Postgrad Med J
29312770	Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. (2017 Dec)	Kalchiem-Dekel O	J Thorac Dis
27388008	Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. (2016 Jul 7)	Park S	BMC Cancer
25488863	Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung. (2015 Feb)	Qiong Z	Lung Cancer
24163741	Molecular biology of lung cancer. (2013 Oct)	Cooper WA	J Thorac Dis
27879019	Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer. (2018 Jan)	Nicos M	Brain Pathol
24300132	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. (2014 Feb)	Sun JM	Lung Cancer
26599269	Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. (2015)	Gautschi O	Oncol Res Treat
29217530	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). (2018 Mar 1)	Aisner DL	Clin Cancer Res